NucktonTJ, AlonsoJA, KalletRH, DanielBM, PittetJF, EisnerMD, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med, 2002; 346(17):1281-1286.
2.
OngT, McClintockDE, KalletRH, WareLB, MatthayMA, LiuKD. Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients. Crit Care Med, 2010; 38(9):1845-1851.
3.
PhillipsCR, ChesnuttMS, SmithSM. Extravascular lung water in sepsis-associated acute respiratory distress syndrome: indexing with predicted body weight improves correlation with severity of illness and survival. Crit Care Med, 2008; 36(1):69-73.
4.
LiuKD, LevittJ, ZhuoH, KalletRH, BradyS, SteingrubJ, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med, 2008; 178(6):618-623.
5.
CharronC, RepesseX, BouferracheK, BodsonL, CastroS, PageB, et al. PaCO2 and alveolar dead space are more relevant than PaO2/FiO2 ratio in monitoring the respiratory response to prone position in ARDS patients: a physiological study. Crit Care, 2011; 15(4):R175.
6.
FengmeiG, JinC, SongqiaoL, CongshanY, YiY. Dead space fraction changes during PEEP titration following lung recruitment in patients with ARDS. Respir Care, 2012; 57(10):1578-1585.
7.
TusmanG, Suarez-SipmannF, BöhmSH, PechT, ReissmannH, MeschinoG, et al. Monitoring dead space during recruitment and PEEP titration in an experimental model. Intensive Care Med, 2006; 32(11):1863-1871.
8.
GoligherEC, CombesA, BrodieD, FergusonND, PesentiAM, RanieriVM, et al. Determinants of the effect of extracorporeal carbon dioxide removal in the SUPERNOVA trial: implications for trial design. Intensive Care Med, 2019; 45(9):1219-1230.
9.
BeitlerJR, ThompsonBT, MatthayMA, TalmorD, LiuKD, ZhuoH, et al. Estimating dead-space fraction for secondary analyses of acute respiratory distress syndrome clinical trials. Crit Care Med, 2015; 43(5):1026-1035.
10.
SinhaP, CalfeeCS, BeitlerJR, SoniN, HoK, MatthayMA, et al. Physiologic analysis and clinical performance of the ventilatory ratio in acute respiratory distress syndrome. Am J Respir Crit Care Med, 2019; 199(3):333-341.
11.
DiantiJS, A.S. GoligherEC. Validity of empirical estimates of physiologic dead space in ARDS. Respir Care, 2021; 66(4):559-565.
12.
KalletRH, ZhuoH, LiuKD, CalfeeCS, MatthayMA, National HeartL, et al. The association between physiologic dead-space fraction and mortality in subjects with ARDS enrolled in a prospective multi-center clinical trial. Respir Care, 2014; 59(11):1611-1618.
13.
SiddikiH, KojicicM, LiG, YilmazM, ThompsonTB, HubmayrRD, et al. Bedside quantification of dead-space fraction using routine clinical data in patients with acute lung injury: secondary analysis of two prospective trials. Crit Care, 2010; 14(4):R141.
14.
PaisFM, SinhaP, LiuKD, MatthayMA. Influence of clinical factors and exclusion criteria on mortality in ards observational studies and randomized controlled trials. Respir Care, 2018; 63(8):1060-1069.
15.
KalletRH, AlonsoJA, PittetJF, MatthayMA. Prognostic value of the pulmonary dead-space fraction during the first 6 days of acute respiratory distress syndrome. Respir Care, 2004; 49(9):1008-1014.
16.
KalletRH, ZhuoH, HoK, LipnickMS, GomezA, MatthayMA. Lung injury etiology and other factors influencing the relationship between dead-space fraction and mortality in ARDS. Respir Care, 2017; 62(10):1241-1248.
